Trials / Not Yet Recruiting
Not Yet RecruitingNCT06685653
Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients
An Exploratory Study of Personalized Neoantigen MRNA Vaccine RGL-270 Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- Nanjing Tianyinshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase IIT , it is an open-label study designed to evaluate the safety and tolerability of personalized mRNA tumor vaccine RGL-270 targeting tumor-specific neoantigens and Adebrelimab (a humanized PD-L1 monoclonal antibody) in patients with resectable NSCLC and those with NSCLC who have relapsed or metastasized after first-line standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adebrelimab+RGL-270 | Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody. Drug: RGL-270 RGL-270 is a mRNA tumor vaccines |
| BIOLOGICAL | Adebrelimab+RGL-270/single RGL-270 | Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody. Drug: RGL-270 RGL-270 is a mRNA tumor vaccines |
Timeline
- Primary completion
- 2026-11-30
- First posted
- 2024-11-12
- Last updated
- 2024-11-12
Source: ClinicalTrials.gov record NCT06685653. Inclusion in this directory is not an endorsement.